Bellevue Group AG
Q1 2021 13F-HR Holdings
Net value change ($000)
+719,488
(8.2%)
New positions
15
Sold out positions
20
Turnover %
2.6%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| MRNA | 60,099 | 19.5% |
| MGNX | 57,011 | 42.2% |
| Accolade, Inc. | 54,067 | 322.6% |
| EPIX | 53,040 | NEW |
| AGIO | 52,266 | 28.7% |
| RVMD | 47,313 | 2986.9% |
| Molecular Templates, Inc. | 42,618 | 70.8% |
| Silk Road Medical Inc | 35,215 | 149.9% |
| ELV | 30,573 | 28.4% |
| INSM | 30,542 | 56.7% |
Top Reduces (Value $000, Stocks/ETFs)
| IONS | -107,761 | -21.1% |
| GW PHARMACEUTICALS PLC | -52,349 | -96.0% |
| ARVN | -49,198 | -26.4% |
| HALO | -47,193 | -27.3% |
| GenMark Diagnostics, Inc. | -38,057 | -100.0% |
| Change Healthcare Inc. | -33,308 | -100.0% |
| Myovant Sciences Ltd. | -25,794 | -19.4% |
| ESPR | -21,703 | -16.2% |
| CRSP | -20,065 | -14.4% |
| VYGR | -19,241 | -99.2% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|